Pfizer Secures Major Deals in Strategic Portfolio Reshuffle

Pharmaceutical giant Pfizer is executing a decisive strategic pivot, marked by two significant transactions. The company has finalized a complete divestiture of its stake in ViiV Healthcare while simultaneously entering a new technology partnership with Novavax. These moves come during a challenging period for shareholders, with the stock having shed over 16% of its value in the past week, highlighting a pressing need for positive catalysts.

A central element of Pfizer's restructuring is the sale of its entire 11.7% minority holding in the HIV specialist ViiV Healthcare. This transaction is set to inject approximately $1.9 billion in immediate liquidity into Pfizer's coffers. Market observers note the timing is critical, as the company navigates declining revenue from its COVID-19 portfolio and prepares for the patent expirations of key blockbuster drugs, including Eliquis and Ibrance, between 2026 and 2028.

The proceeds are earmarked for strengthening Pfizer's internal development pipeline and allocating capital to high-growth therapeutic areas. While GSK retains its majority control of ViiV, Pfizer's exit concludes a 17-year partnership, allowing the company to redirect resources more strategically toward its core priorities.

Licensing Agreement to Bolster Vaccine Platform

Concurrent with the divestment, Pfizer announced a licensing agreement with Novavax. The deal grants Pfizer access to Novavax's established Matrix-M adjuvant technology for use in developing novel vaccines. Under the terms, Pfizer will make an upfront payment of $30 million, with potential additional milestone payments totaling up to $500 million.

Should investors sell immediately? Or is it worth buying Pfizer?

Financial analysts interpret this agreement as a firm commitment to advancing Pfizer's vaccine portfolio. By integrating this external innovation, the company aims to enhance the efficacy of future vaccine candidates and complement its internal research and development efforts more efficiently.

Upcoming Financial Calendar in Focus

Investor attention now turns to imminent financial events. Pfizer shares will begin trading ex-dividend on January 23, 2026. Of greater significance will be February 3, 2026, when the company releases its fourth-quarter and full-year 2025 results.

For the current 2026 fiscal year, Pfizer's management has provided revenue guidance in the range of $59.5 billion to $62.5 billion. The company also forecasts an adjusted earnings per share of between $2.80 and $3.00.